Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!
Journal of the Society for Gynecologic Investigation
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Tam, K. F.
Right arrow Articles by Ngan, Y. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tam, K. F.
Right arrow Articles by Ng, T. Y.
Right arrow Articles by Tsang, P. C. K.
Right arrow Articles by Li, C. F.
Right arrow Articles by Ngan, Y. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Potential Use of the Adenosine Triphosphate Cell Viability Assay in Endometrial Cancer

Kar Fai Tam, MRCOG

Gynaecological Oncology Division, Department of Obsterics and Gynaecology, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China tamkfa{at}netvigator.com

Tong Yow Ng, FRCOG

Percy Chi Kit Tsang, MSc

Chiu Fai Li, MRCOG

Yuen Sheung Ngan, FRCOG

Gynaecological Oncology Division, Department of Obsterics and Gynaecology, The University of Hong Kong, Queen Mary Hospital, Hong Kong SAR, China

Objective: Adenosine triphosphate cell viability assay (ATP-CVA) was used prevously to evaluate chemotherapy in uterine cancer cell lines. In this study, we have performed the ATP-CVA on endometrial cancer patients to study the feasibility of using ATP-CVA in endometrial cancer to determine the intrinsic chemosensitivity of the cytotoxic drugs.

Methods: Thirty-three patients with endometrial adenocarcinoma who presented for a staging operation were recruited. Endometrial cancer samples were obtained at the time of operation. In vitro ATP-CVA and chemosensitivity testing was performed using cisplatin, carboplatin, paclitaxel, etoposide, doxorubicin, 4-epidoxorubicin, and topotecan.

Results: Thirty-two of the 33 endometrial cancer samples were evaluable for SF50 (survival fraction at 50% of the peak plasma concentration [PPC]) using ATP-CVA. The median SF50 of carboplatin (0.33) was significantly less than the median SF50 of cisplatin (0.71), topotecan (0.93), paclitaxel (0.68), doxorubicin (1.0), etoposide (0.70), or 4-epidoxorubicin (0.88) (Wilcoxon signed rank test, P <.001).

Conclusion: This study showed the feasibility of using the ATP-CVA in endometrial cancer to determine the intrinsic chemosensitivity of cytotoxic drugs.

Key Words: ATP cell viability assay • endometrial cancer • chemosensitivity

Journal of the Society for Gynecologic Investigation, Vol. 13, No. 7, 518-522 (2006)
DOI: 10.1016/j.jsgi.2006.06.004
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?